IGF-II and Insulin Receptors in Neural Stem Cells

神经干细胞中的 IGF-II 和胰岛素受体

基本信息

  • 批准号:
    8734489
  • 负责人:
  • 金额:
    $ 23.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-15 至 2017-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Neural precursors have long been of interest to developmental biologists. These cells have recently gained the interest of the broader neuroscience community because of their involvement in olfaction, learning and memory, cognitive decline with aging and their potential to replace neurons or glial cells that have died a a consequence of brain injury or disease. The cells that are of significant interest are the neural stem cells (NSCs). These cells naturally reside within specific niches where they receive signals that are necessary to maintain them in a primitive state. To date, the possibility that IGF-II is a necessary component of the stem cell niche has not been considered largely because IGF-II has been regarded as a fetal growth factor. However, IGF-II is expressed at high levels within the choroid plexus, which produces the cerebrospinal fluid that is readily accessible to the NSCs because they extend a process directly into the ventricle that is bathed by cerebrospinal fluid. Whereas both IGF-II and IGF-I activate the IGF type 1 receptor (IGF-1R), IGF-II also binds to a splice variant isoform of the insulin receptor (IR-A) supporting distinct roles for IGF-II versus IGF-I. The overall hypothesis of this proposal is that IGF-II is essential for NSC self-renewal, maintenance and growth through the insulin receptor. Our overall hypothesis will be tested using inducible Cre driver lines to achieve both temporal discrete deletion of IGF-II or insulin receptors. Studies will be performed at the molecular, cellular and behavioral levels. Identifying IGF-II as necessary to sustain NSCs as primitive cells will be a significant scientific advance. Moreover, establishing which signaling receptor and downstream transcription factors are activated by this signal might well provide insights into new strategies to amplify these important cells to promote brain growth, maintain cell replacement across the lifespan and enhance cell replacement in the diseased or damaged brain. IGF-II is also expressed in other organs where there are adult stem cells, yet a role for IGF-II in adult stem cell maintenance has not been explored in mammalian tissues. Therefore, upon completing the proposed experiments we will be uniquely positioned to submit an R01 application to investigate these important and timely issues.
描述(由申请人提供):神经前体一直是发育生物学家的兴趣。这些细胞最近引起了更广泛的神经科学界的兴趣,因为它们参与嗅觉,学习和记忆,随着年龄的增长认知能力下降,以及它们取代因脑损伤或疾病而死亡的神经元或神经胶质细胞的潜力。重要的细胞是神经细胞, 干细胞(NSC)。这些细胞自然地驻留在特定的小生境中,在那里它们接收维持它们处于原始状态所必需的信号。到目前为止,IGF-II是一种 由于IGF-II被认为是一种胎儿生长因子,因此,干细胞龛的必要成分在很大程度上没有得到考虑。然而,IGF-II在脉络丛内以高水平表达,脉络丛产生容易接近NSC的脑脊液,因为它们将过程直接延伸到被脑脊液浸泡的脑室中。尽管IGF-II和IGF-I均激活IGF 1型受体(IGF-1 R),但IGF-II还结合胰岛素受体(IR-A)的剪接变体同种型,支持IGF-II与IGF-I的不同作用。该建议的总体假设是IGF-II通过胰岛素受体对NSC自我更新、维持和生长至关重要。我们的总体假设将使用诱导型Cre驱动系进行测试,以实现IGF-II或胰岛素受体的时间离散缺失。研究将在分子、细胞和行为水平上进行。 识别 IGF-II作为维持神经干细胞作为原始细胞所必需的将是一个重大的科学进步。此外,确定哪些信号受体和下游转录因子被这种信号激活可能会为放大这些重要的信号的新策略提供见解。 细胞促进大脑生长,在整个生命周期中保持细胞替换,并增强患病或受损大脑中的细胞替换。IGF-II也表达于存在成体干细胞的其他器官中,但IGF-II在成体干细胞维持中的作用尚未在哺乳动物组织中探索。因此,在完成拟议的实验后,我们将处于独特的地位,提交R 01申请,以调查这些重要而及时的问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN W LEVISON其他文献

STEVEN W LEVISON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN W LEVISON', 18)}}的其他基金

Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischema
鼻内 LIF 可改善围产期缺氧缺血的神经功能恢复
  • 批准号:
    10350660
  • 财政年份:
    2020
  • 资助金额:
    $ 23.61万
  • 项目类别:
Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischema
鼻内 LIF 可改善围产期缺氧缺血的神经功能恢复
  • 批准号:
    9980145
  • 财政年份:
    2020
  • 资助金额:
    $ 23.61万
  • 项目类别:
Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischema
鼻内 LIF 可改善围产期缺氧缺血的神经功能恢复
  • 批准号:
    10555280
  • 财政年份:
    2020
  • 资助金额:
    $ 23.61万
  • 项目类别:
American Society for Neurochemistry 44th Annual Meeting
美国神经化学学会第 44 届年会
  • 批准号:
    8529173
  • 财政年份:
    2013
  • 资助金额:
    $ 23.61万
  • 项目类别:
IGF-II and Insulin Receptors in Neural Stem Cells
神经干细胞中的 IGF-II 和胰岛素受体
  • 批准号:
    8643924
  • 财政年份:
    2013
  • 资助金额:
    $ 23.61万
  • 项目类别:
American Society for Neurochemistry 43rd Annual Meeting
美国神经化学学会第 43 届年会
  • 批准号:
    8319005
  • 财政年份:
    2012
  • 资助金额:
    $ 23.61万
  • 项目类别:
Glial Dysgenesis in the Injured Developing Brain
受伤发育中的大脑中的神经胶质发育不全
  • 批准号:
    8066317
  • 财政年份:
    2010
  • 资助金额:
    $ 23.61万
  • 项目类别:
Glial Dysgenesis in the Injured Developing Brain
受伤发育中的大脑中的神经胶质发育不全
  • 批准号:
    7889970
  • 财政年份:
    2010
  • 资助金额:
    $ 23.61万
  • 项目类别:
Glial Dysgenesis in the Injured Developing Brain
受伤发育中的大脑中的神经胶质发育不全
  • 批准号:
    8717070
  • 财政年份:
    2010
  • 资助金额:
    $ 23.61万
  • 项目类别:
Glial Dysgenesis in the Injured Developing Brain
受伤发育中的大脑中的神经胶质发育不全
  • 批准号:
    8443451
  • 财政年份:
    2010
  • 资助金额:
    $ 23.61万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.61万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了